Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KZIA - Kazia Therapeutics Limited - ADR


IEX Last Trade
0.4216
0.030   7.139%

Share volume: 1,207,752
Last Updated: Fri 30 Aug 2024 09:55:20 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.39
0.03
7.69%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
17.58%
1 Month
12.37%
3 Months
69.52%
6 Months
62.81%
1 Year
-52.55%
2 Year
-71.40%
Key data
Stock price
$0.42
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.19 - $1.58
52 WEEK CHANGE
-$0.56
MARKET CAP 
11.159 M
YIELD 
N/A
SHARES OUTSTANDING 
26.362 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$836,796
AVERAGE 30 VOLUME 
$744,377
Company detail
CEO:
Region: US
Website: novogen.com
Employees: 60
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

innovative. focused. agile. kazia therapeutics is an agile, oncology-focused biotechnology company, based in sydney, australia. we have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications. our lead program is gdc-0084, a small molecule inhibitor of the pi3k / akt / mtor pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. licensed from genentech in late 2016, gdc-0084 is anticipated to enter phase ii clinical trials in 2017. trxe-002-1, or cantrixil is kazia’s second drug development candidate under development as a treatment for ovarian cancer. the chemotherapeutic is currently undergoing a phase 1 clinical trial in hospitals across australia and the united states. initial data on this trial is expected to be reported early in 2018. kazia therapeutics is trading under the following tickers: asx: kza nasdaq: kzia for more information, please visi

Recent news